Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan

The coronavirus disease (COVID-19) pandemic continues to threaten global public health. Remdesivir and monoclonal antibodies have shown promise for COVID-19 treatment of patients who are immunocompromised, including those with cancer, transplant recipients, and those with autoimmune disorder. Howeve...

Full description

Bibliographic Details
Main Authors: Jun Hirai, Nobuaki Mori, Daisuke Sakanashi, Wataru Ohashi, Yuichi Shibata, Nobuhiro Asai, Hideo Kato, Mao Hagihara, Hiroshige Mikamo
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Viruses
Subjects:
COVID-19
immunocompromised
remdesivir
monoclonal antibodies
combination
Online Access:https://www.mdpi.com/1999-4915/15/9/1952

Similar Items

Similar Items